By Turna Ray

CYP2C19 alleles ⢀ which various studies have shown to limit response to the anti-platelet drug Plavix in carriers of the polymorphisms ⢀ did not have the same impact on patients' ability to metabolize the drug in a study published in the New England Journal of Medicine last week.

The authors of the study said they believe the data raises doubts on the clinical utility of genotyping for CYP2C19 loss-of-function alleles as a way to direct Plavix therapy in patients with acute coronary syndrome and atrial fibrillation.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.